Pediatrics – Cardiology
Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
1 Apr, 2022 | 08:45h | UTCCommentary: Network meta-analysis rates treatments for Kawasaki disease – medwire News
Review: Sudden cardiac death in congenital heart disease.
30 Mar, 2022 | 10:17h | UTCSudden cardiac death in congenital heart disease – European Heart Journal
Commentary on Twitter
Sudden cardiac death in congenital heart disease – state-of-the-art review https://t.co/Oz5Lbp8XKZ @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/Bu6m4tK8rL
— European Society of Cardiology Journals (@ESC_Journals) March 28, 2022
Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals.
29 Mar, 2022 | 10:09h | UTCRelated:
Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.
Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
AHA Scientific Statement: Advances in managing transition to adulthood for adolescents with congenital heart disease.
18 Mar, 2022 | 08:19h | UTCNews Release: For youth with a heart defect, shift to adult-focused care is key to health, quality of life – American Heart Association
RCT: In pediatric ICUs, a bundled intervention that emphasized a physiologically focused cardiopulmonary resuscitation training did not improve outcomes in cardiac arrest.
11 Mar, 2022 | 09:37h | UTCEffect of Physiologic Point-of-Care Cardiopulmonary Resuscitation Training on Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary: CPR Intervention Failed to Improve Survival in Kids With Cardiac Arrest — Physiologically focused CPR training did not lead to difference in survival to discharge – MedPage Today (free registration required)
Commentary on Twitter
Among patients in pediatric ICUs, a bundled intervention that emphasized physiologically focused CPR training and structured clinical event debriefing did not significantly improve patient survival to hospital discharge with favorable neurologic outcome. https://t.co/MbmmSM0Xrt
— JAMA (@JAMA_current) March 8, 2022
ACR/Vasculitis Foundation Guideline for the management of Kawasaki Disease.
9 Mar, 2022 | 10:01h | UTC
AAP Clinical Report: Recognition and management of cardiovascular insufficiency in the very low birth weight newborn.
4 Mar, 2022 | 08:54h | UTC
Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.
3 Mar, 2022 | 08:43h | UTCMyocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics
Commentary: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI
Related:
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Anti-inflammatory treatment of Kawasaki Disease: comparison of current guidelines and perspectives.
25 Feb, 2022 | 10:29h | UTC
External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy.
17 Feb, 2022 | 08:21h | UTC
Commentary on Twitter
Check out #EJPC first external validation of the HCM Risk-Kids model https://t.co/EWaiApaxN5 #hypertrophic #cardiomyopathy #genetics #suddendeath #SCD @jodieingles27 @CSHeartResearch @CarolynHoMD @RumanaOmar @jpkaski @m_piepoli @SilCastelletti @paolo_emilio @EAPCPresident pic.twitter.com/rOVk1ynwWl
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2022
Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer.
9 Feb, 2022 | 10:06h | UTCRelated:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.
9 Feb, 2022 | 10:08h | UTCRelated:
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Commentary on Twitter
The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v— Eric Topol (@EricTopol) February 9, 2022
Review: Prevention of atherosclerosis from childhood.
2 Feb, 2022 | 08:12h | UTCPrevention of atherosclerosis from childhood – Nature Reviews Cardiology (if the link is paywalled, try this one)
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
30 Jan, 2022 | 14:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Related:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Commentary on Twitter
Data from the Israeli MOH show estimates of myocarditis risk in the 21 days after a first & second dose of vaccine were 0.56 per 100,000 and 8.09 per 100,000 among male recipients and 0 per 100,000 and 0.69 per 100,000 among females. https://t.co/M6kxVA2toS pic.twitter.com/bQ4TBmcrj4
— NEJM (@NEJM) January 29, 2022
Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.
26 Jan, 2022 | 02:23h | UTCRelated:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.
25 Jan, 2022 | 09:43h | UTCNews release: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians
Related:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Global, regional, and national time trends in mortality for congenital heart disease, 1990–2019: An age-period-cohort analysis for the Global Burden of Disease 2019 study.
25 Jan, 2022 | 09:13h | UTC
Commentary on Twitter
A new study using data from the #GBD 2019 study estimated trends in congenital #heartdisease (CHD) mortality in 204 countries and territories over the past 30 years.
Read more here: https://t.co/6NtW0TYMAG pic.twitter.com/VLCU9OuOwx
— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) January 14, 2022
Heart function recovered quickly in children with COVID-19-related multisystem inflammatory syndrome (MIS-C).
20 Jan, 2022 | 09:26h | UTCNews Release: Heart function recovered quickly in children with COVID-19-related MIS-C condition – American Heart Association
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
9 Jan, 2022 | 01:05h | UTCRisk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv
Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:
Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.
7 Dec, 2021 | 10:19h | UTCNews Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association
#AHA21 – RCT: Among children and adolescents who had screening echocardiograms and were identified as having latent rheumatic heart disease, secondary antibiotic prophylaxis with penicillin G benzathine for 2 years was associated with reduced echocardiographic progression (0.8 vs. 8.2% in the control group).
14 Nov, 2021 | 20:03h | UTCSecondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology
Commentaries on Twitter
One of most important studies ever Rheumatic Heart Disease @NEJM https://t.co/U8FuNHLqCJ RCT evidence 2ry prophylaxis reduces progression latent RhD pic.twitter.com/UycTElr7QM
— Michael Marks (@dr_michaelmarks) November 13, 2021
Penicillin slowed the devastating impact of rheumatic heart disease among children in Uganda. Findings of a large-scale, randomized controlled trial were completed in Uganda. Group A strep underlies rheumatic heart disease. New England Journal of Medicine https://t.co/1PKFJ12FvC
— delthia ricks ? (@DelthiaRicks) November 13, 2021
AHA Scientific Statement: Sleep‐disordered breathing and cardiovascular disease in children and adolescents.
23 Sep, 2021 | 10:02h | UTCNews release: Obstructive sleep apnea is common in kids and may impact blood pressure, heart health – American Heart Association
AHA Scientific Statement: Genetic testing for heritable cardiovascular diseases in pediatric patients.
6 Sep, 2021 | 10:33h | UTCNews release: Genetic testing in children for heart disorders should be family-centered, include counseling – American Heart Association
Commentary on Twitter
Just out @Circ_Gen Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement: American Heart Association! Fantastic leadership @APLandstrom Honored to be part of it @GenPrecisionMed @AHA_Research #CardioTwitter https://t.co/zEc9tDYAeC pic.twitter.com/49RAkuYCZG
— Prof Chris Semsarian (@CSHeartResearch) August 20, 2021
AAP Policy Statement | Incorporate cardiac risk screening for all youths at least every 3 years.
23 Jul, 2021 | 10:19h | UTCNews release: Policy: Incorporate cardiac risk screening for all youths at least every 3 years – American Academy of Pediatrics
Policy Statement: Sudden Death in the Young: Information for the Primary Care Provider – Pediatrics
CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected”.
9 Jul, 2021 | 10:17h | UTC
Commentary on Twitter
In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. The benefits of vaccination in preventing illness & death outweigh the rare risk of heart inflammation after vaccination. More: https://t.co/iPjbhU5jeV. pic.twitter.com/IggrZ4DX7L
— CDC (@CDCgov) July 6, 2021